Scholarlink

<p>The increasing prevalence of cancers, their economic impact and the complications associated with existing treatments, have stimulated research to better understand the mechanisms involved in their aetiology and the development of more effective diagnostic and treatment methods. Olverembatinib (HQP1351 or GZD824) is a new third-generation tyrosine kinase inhibitor (TKI), that is being investigated for its potential application in the treatment of several cancers, with a focus on chronic myeloid leukemia (CML). This review attempts to summarise the pre-clinical and clinical studies in hematological and non-hematological malignancies of this agent.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies—a comprehensive review of clinical outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月17日

查看全文
  • Sina Sadati,
  • Sara Yazdizadeh,
  • Seyed Mohsen Razavi,
  • Mina Homayoonfal,
  • Gordon A. Ferns,
  • Fatemeh Divani,
  • Hamed Mirzaei

摘要

The increasing prevalence of cancers, their economic impact and the complications associated with existing treatments, have stimulated research to better understand the mechanisms involved in their aetiology and the development of more effective diagnostic and treatment methods. Olverembatinib (HQP1351 or GZD824) is a new third-generation tyrosine kinase inhibitor (TKI), that is being investigated for its potential application in the treatment of several cancers, with a focus on chronic myeloid leukemia (CML). This review attempts to summarise the pre-clinical and clinical studies in hematological and non-hematological malignancies of this agent.